SCHEMBL29812119

SCHEMBL29812119

C#CCN(C(=O)OC(C)(C)C)c1ccc(S(C)(=O)=O)cc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.38
▸ POLQ O75417 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ RORC P51449 1/20 0.33
▸ CRHR1 P34998 1/20 0.33
▸ KIF11 P52732 1/20 0.33
▸ GPR119 Q8TDV5 3/20 0.33
▸ KCNQ4 P56696 1/20 0.32
▸ KCNQ5 Q9NR82 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ ESR1 P03372 1/20 0.32
▸ PLK1 P53350 2/20 0.32
▸ CACNA1B Q00975 3/20 0.32
▸ NR1I2 O75469 1/20 0.32
▸ CACNA1G O43497 1/20 0.31
▸ CACNA1C Q13936 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23144395 1.00 HRH4 (0.38) HRH4POLQCDK1CDK2KDR
SCHEMBL20927651 0.85 F2 (0.34) GPR119KCNQ4KCNQ5
SCHEMBL23144835 0.85 HRH4 (0.43) HRH4POLQCDK1CDK2KDR
SCHEMBL23155582 0.85 HRH4 (0.36) HRH4RORCGPR119CACNA1BNR1I2
SCHEMBL29811716 0.85 HRH4 (0.36) HRH4RORCGPR119CACNA1BNR1I2
SCHEMBL23144580 0.84 PDK1 (0.37) GPR119LMNAKMT2A
SCHEMBL29811656 0.84 PDK1 (0.37) GPR119LMNAKMT2A
SCHEMBL31363665 0.84 GPR119 (0.33) GPR119KCNQ4KCNQ5
SCHEMBL23144640 0.83 SMN1; SMN2 (0.40) GPR119LMNAKMT2A
SCHEMBL29811519 0.83 SMN1; SMN2 (0.40) GPR119LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-04-09 — — US disclosed
EP-4644387-A2 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2025-11-05 — — EP disclosed
US-12428406-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 — — US disclosed
US-20220315564-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2022-10-06 — — US disclosed
EP-4034104-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2022-08-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428406-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS HRH4 4627/4885POLQ 139/4885CDK1 702/4885
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS HRH4 4627/4885POLQ 139/4885CDK1 702/4885
US-20220315564-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS HRH4 4627/4885POLQ 139/4885CDK1 702/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS HRH4 4627/4885POLQ 139/4885CDK1 702/4885
US-20260098032-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, MDM2 HRH4 4814/4885POLQ 714/4885CDK1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback